Adma Biologics reported $25.44M in Cost of Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Adma Biologics ADMA:US $ 25.44M 2.57M
Agile Therapeutics AGRX:US 1.53M 4.17M
Alnylam Pharmaceuticals ALNY:US $ 35.63M 2.04M
Biocryst Pharmaceuticals BCRX:US $ 0.24M 0.18M
China Cord Blood CO:US 47.28M 1.07M
Dynavax Technologies DVAX:US $ 39.96M 34.05M
Takeda 4502:JP Y 308380M 26976M